A Sneak Peek of Citi’s 15th Annual BioPharma 2020 Boston
Like almost all of this year’s conferences, Citi’s 15e The BioPharma 2020 annual conference is being held virtually. Scheduled to run from September 9-10, there were, however, a few presentations on September 8. Here is a look at some of the companies that made presentations.
Bristol Myers SquibbRupert Vessey President and Chief Medical Officer Tim Power, Head of Investor Relations, and Samit Hirawat, Chief Medical Officer and Head of Development, made a presentation September 8. Hiarawat, speaking about the recent merger with Celgene, noted: “What we’re trying to do as we build a culture of a business now over the past seven, eight months, COVID has certainly given us a different perspective and we have certainly been very nimble and adaptable.
Vessey noted that “Celgene brought into the mix… a much more diverse footprint and we’re trying to capitalize on that. So we now have a fully functional yet very innovative research and development facility in San Diego, Seattle Bay Area, Seattle and obviously bringing our two organizations together in Cambridge in a wonderful new facility. “
Much of the discussion also took place in the company’s liso-cel. The treatment, lisocabtagene maraleucel, is an experimental CAR-T cell therapy directed against CD19 for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (R / R), mediastinal lymphoma primary B-cell (PMBCL) and follicular lymphoma. grade 3B (FL3B) after at least two previous treatments. The FDA has yet to inspect its manufacturing facilities, in large part because of the pandemic. Hirawat said, “We are working closely with the FDA to keep this request on track and as you know the PDUFA date is November. We still have time to go. “
Endo International indicated management representatives will organize virtual meetings at the conference on September 10. second quarter report on August 5, revenue was down 2% to $ 688 million from a year earlier, but on July 6, the U.S. Food and Drug Administration (FDA) approved its Qwo (collagenase clostridium histolyticum-aaes) , the first injectable treatment for cellulite.
Amgen plans to present at 2:25 p.m. ET on Thursday, September 10. Murdo Gordon, Executive Vice President of Global Business Operations and Peter H. Griffith, Executive Vice President and Chief Financial Officer, will make a presentation. More recently, the company announced positive data of the Phase IIIb HAUSER-RCT trial of Repatha (evolocumab) in pediatric patients, aged 10 to 17 years, with heterozygous familial hypercholesterolaemia (HeFH). Repatha, along with statins and other lipid-lowering drugs, significantly lowered low-density lipoprotein (LDL-C) cholesterol compared to placebo.
Rain therapy conducted a business review at the conference on September 8. On September 3, the company closed on a Series B financing valued at $ 63 million. It was led by Boxer Capital and followed by new investors Cormorant Asset Management, Samsara BioCapital, Janus Henderson Investors and Logos Capital. Existing investors include BVF Partners and Perceptive Advisers. The company plans to use the funds to advance its portfolio of targeted cancer therapies and general corporate spending. One of the programs is RAIN-32, an MDM2 inhibitor recently licensed by Daiichi Sankyo Company.
Merck‘s Roy Baynes, senior vice president and head of global clinical development, and chief medical officer, Merck Research Laboratories, is participant in a fireside chat on September 10 at 8:00 a.m. EDT. On September 9, the company ad the first positive results from two phase III studies in adults of V114, its investigational 15-valent pneumococcal conjugate vaccine, including a pivotal trial. The trials achieved their primary immunogenicity goals.
Medicine Discthe general manager of John Quisel made a presentation Tuesday, September 8. Quisel joined the company on January 28. On August 3, the company ad that Jonathan Yu has been named senior vice president of corporate strategy and William Save has been named vice president of clinical development.
Neurocrine biosciences present September 9 at 12:35 p.m. ET. Kevin Gorman, General Manager, made the presentation. On August 3, the company made its second quarter financial report. Revenue for the quarter totaled $ 302.4 million and for the six-month period, $ 539.5 million. Ingrezza’s net product sales for the quarter were $ 268 million, a 48% year-over-year increase. In April 2020, the FDA approved the Company’s Ongentys (opicapone) as an adjunct to levodopa / carbidopa in patients with Parkinson’s disease with “off” episodes.
Therapeutic Decibel present Sept. 8 at 1:10 p.m. ET. The presentation was made by Laurence Reid, President and CEO. More recently, in March 2020, the company ad that data from phase Ia clinical trials have demonstrated the safety and tolerability of its lead candidate, DB-020. The data was published in the journal Investigational New Drugs. Therapy is under development to prevent cisplatin-induced hearing loss. The data suggests that the drug would not impact the effectiveness of treatment with cisplatin throughout the body.